🧪
hypothesis

Soluble LRP1 Fragments Serve as Blood-Based Indicators of Impaired Aβ Efflux and BBB Transporter Dysfunction

Hypothesis

Soluble LRP1 Fragments Serve as Blood-Based Indicators of Impaired Aβ Efflux and BBB Transporter Dysfunction

LRP1 at brain microvascular endothelium mediates Aβ export from CNS to periphery.
🧬 LRP1🎯 Composite 49%💱 $0.61▲2.1%proposed
neurodegeneration
EvidencePending (0%)📖 0 cit🗣 1 debates 3 support 3 oppose
✓ All Quality Gates Passed
Mechanistic 0.55 (15%) Evidence 0.30 (15%) Novelty 0.00 (12%) Feasibility 0.00 (12%) Impact 0.00 (12%) Druggability 0.00 (10%) Safety 0.00 (8%) Competition 0.00 (6%) Data Avail. 0.00 (5%) Reproducible 0.00 (5%) KG Connect 0.19 (8%) 0.485 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite49%

🧪 Overview

LRP1 at brain microvascular endothelium mediates Aβ export from CNS to periphery. AD-associated inflammation activates ADAM10/17-mediated proteolytic shedding of LRP1's extracellular domain (sLRP1), reducing endothelial Aβ clearance capacity. However, LRP1 is ubiquitously expressed (liver, lung, macrophages), and peripheral sources dominate plasma sLRP1, making brain-specific interpretation unreliable.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["AD-associated<br/>Inflammation"]
    B["ADAM10/17-mediated<br/>LRP1 Shedding"]
    C["sLRP1<br/>Fragment Release"]
    D["A beta Efflux<br/>Impairment"]
    E["Brain A beta<br/>Accumulation"]
    F["BBB Transporter<br/>Dysfunction"]
    G["Peripheral Blood<br/>sLRP1 Signal"]
    A --> B
    B --> C
    C --> D
    D --> E
    C --> G
    E --> F
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style C fill:#e65100,stroke:#ffab91,color:#ffab91
    style G fill:#e65100,stroke:#ffab91,color:#ffab91

⚖️ Evidence

⚖️ Evidence Matrix3 supports3 contradicts
Supports
LRP1 mediates Aβ efflux across the BBB, with expression declining in AD
PMID:20847311
Supports
sLRP1 levels in plasma inversely correlate with brain Aβ burden and cognitive function
PMID:22699977
Supports
ADAM10/17 responsible for LRP1 ectodomain shedding in response to inflammatory stimuli
PMID:27784180
Contradicts
Liver LRP1 significantly contributes to plasma sLRP1
PMID:33998682
Contradicts
LRP1 expression on peripheral monocytes correlates with AD risk
PMID:31305942
Contradicts
Majority of circulating sLRP1 originates from peripheral tissues
PMID:33998682
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — LRP1

🧬 PDB 2FCW Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for LRP1 from GTEx v10.

Cerebellum128 Cerebellar Hemisphere98.4median TPM (GTEx v10)

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for LRP1 →

No DepMap CRISPR Chronos data found for LRP1.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.1247
Events (7d)
1
Price History
▲2.1%

💾 Resource Usage

No resource usage or linked notebooks recorded for this hypothesis yet.

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF we stratify early-stage AD patients by degree of BBB dysfunction (using dynamic contrast-enhanced MRI permeability metrics) THEN plasma sLRP1 fragment concentrations will be significantly elevated Plasma sLRP1 fragment levels (measured by ELISA targeting the extracellular domain) will be positively correlated with BBB permeability (Ktrans values) in AD pa— no observation —pending0.65
IF we chronically inhibit ADAM10/17 activity (via pharmaceutical blockade or genetic knockdown) in 5xFAD transgenic mice starting at 3 months of age THEN brain microvascular endothelial sLRP1 protein ADAM10/17 inhibition will reduce proteolytic shedding of LRP1 at the brain endothelium, preserving full-length LRP1 function and enhancing Aβ efflux capacity, a— no observation —pending0.58
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF we stratify early-stage AD patients by degree of BBB dysfunction (using dynamic contrast-enhanced MRI permeability metrics) THEN plasma sLRP1 fragment concentrations will be significantly elevated (≥30% increase) in the high BBB dysfunction stratum compared to age-matched controls without BBB imp
Predicted outcome: Plasma sLRP1 fragment levels (measured by ELISA targeting the extracellular domain) will be positively correlated with BBB permeability (Ktrans values
Falsification: No significant correlation between plasma sLRP1 and MRI-measured BBB permeability; or sLRP1 levels are indistinguishable between AD patients with high vs. low BBB dysfunction, indicating peripheral so
pendingconf 58%
IF we chronically inhibit ADAM10/17 activity (via pharmaceutical blockade or genetic knockdown) in 5xFAD transgenic mice starting at 3 months of age THEN brain microvascular endothelial sLRP1 protein levels will increase (≥40%) and cerebral Aβ40/42 accumulation will decrease (≥25%) compared to vehic
Predicted outcome: ADAM10/17 inhibition will reduce proteolytic shedding of LRP1 at the brain endothelium, preserving full-length LRP1 function and enhancing Aβ efflux c
Falsification: sLRP1 fragment levels decrease as expected with ADAM10/17 inhibition but Aβ burden shows no significant reduction (p>0.05), indicating sLRP1 shedding is not causally linked to impaired Aβ clearance, o
View on SciDEX ↗